Sign In
Upcoming Event
Free Newsletter
Annapolis-based PharmAthene gets $5.7M DoD contract
//August 16, 2011
ANNAPOLIS — PharmAthene Inc. of Annapolis, a company developing medical defenses against biological and chemical threats, said it has been awarded a $5.7 million, 18-month contract by the U.S. Department of Defense to continue development of a counter-measure to ward off the physical effects of chemical nerve agents.
According to the company, preclinical studies in animals suggest that the treatment, dubbed rBChE, has the potential to provide significant protection against chemical nerve agent poisoning when administered prophylactically (prior to exposure to nerve agent), and also may increase survival when administered therapeutically (following nerve agent exposure).
